EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dupilumab normalizes the eosinophilic esophagitis disease transcriptome

Wei Keat Lim, Matthew F Wipperman, Marc E Rothenberg, Margaret H Collins, Sara C Hamon, Mirna Chehade, Jonathan M Spergel, Kaitlyn M Gayvert, Peter J Ehmann, Julie E Horowitz, Annamaria B Farrell, Evan S Dellon und 9 weitere

Journal of Allergy and Clinical Immunology · 2026-08 · 158 (2) · 542-554

DOI: 10.1016/j.jaci.2026.01.033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-08. Verfasst von Wei Keat Lim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc, Tarrytown, NY. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized, Transcriptome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi US, Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eosinophilic esophagitis (EoE) is a type 2 inflammatory disease of the esophagus, characterized by eosinophilic inflammation and an altered esophageal transcriptome. Dupilumab, a fully human mAb that blocks IL-4 and IL-13 signaling, is approved for use in multiple type 2 inflammatory diseases, including EoE, where it produces histologic, symptomatic, and endoscopic improvements in pediatric, adolescent, and adult patients. OBJECTIVE: We sought to investigate the effect of dupilumab on the dysregulated esophageal transcriptome in pediatric, adolescent, and adult patients with EoE. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02379052, NCT03633617, and NCT04394351. METHODS: Changes in the esophageal transcriptome were analyzed from pretreatment and posttreatment esophageal biopsy specimens provided by pediatric, adolescent, and adult patients with EoE who participated in 1 of 3 placebo-controlled clinical trials of dupilumab. RESULTS: Dupilumab treatment resulted in marked normalization of the EoE disease transcriptome, including gene signatures associated with eosinophils as well as other aspects of type 2 inflammation and esophageal dysfunction including mast cells, fibrosis, barrier function, and other cell functions and pathways. Overall, gene ontology enrichment analysis identified 41 biological processes dysregulated in EoE that were normalized with dupilumab treatment, including processes likely to be eosinophil independent. Transcriptome changes were comparable and sustained through week 52 across pediatric, adolescent, and adult patients with EoE. CONCLUSIONS: IL-4 and IL-13 are the critical drivers of the molecular differences in the esophageal mucosa of patients with EoE compared with control subjects, consistent with the clinical benefit of dupilumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedTranscriptomeHumansAdolescentChildAdultMaleFemaleInterleukin-4Interleukin-13Young AdultEsophagusEosinophilsMiddle Aged

Stichwörter der Autor:innen

Eosinophilic esophagitisdupilumabgene expressiontranscriptometype 2 inflammation

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabInterleukin-4Interleukin-13

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals Inc, Tarrytown, NY.
  • Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Division of Pathology and Laboratory Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

Förderung

  • Sanofi US
  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Lim, W. K., Wipperman, M. F., Rothenberg, M. E., Collins, M. H., Hamon, S. C., Chehade, M., Spergel, J. M., Gayvert, K. M., Ehmann, P. J., Horowitz, J. E., Farrell, A. B., Dellon, E. S., Maloney, J., Radin, A., Louisias, M., Wolfe, K., Akinlade, B., Ajithdoss, D. K., Herman, G., …, & Hamilton, J. D. (2026). Dupilumab normalizes the eosinophilic esophagitis disease transcriptome. Journal of Allergy and Clinical Immunology, 158(2), 542-554. https://doi.org/10.1016/j.jaci.2026.01.033

Vancouver

Lim WK, Wipperman MF, Rothenberg ME, Collins MH, Hamon SC, Chehade M, et al. Dupilumab normalizes the eosinophilic esophagitis disease transcriptome. Journal of Allergy and Clinical Immunology. 2026;158(2):542-554. doi:10.1016/j.jaci.2026.01.033

BibTeX
@article{Lim2026,
  author = {Lim, Wei Keat and Wipperman, Matthew F and Rothenberg, Marc E and Collins, Margaret H and Hamon, Sara C and Chehade, Mirna and Spergel, Jonathan M and Gayvert, Kaitlyn M and Ehmann, Peter J and Horowitz, Julie E and Farrell, Annamaria B and Dellon, Evan S and Maloney, Jennifer and Radin, Allen and Louisias, Margee and Wolfe, Kelley and Akinlade, Bolanle and Ajithdoss, Dharani K and Herman, Gary and Yancopoulos, George D and Hamilton, Jennifer D},
  title = {Dupilumab normalizes the eosinophilic esophagitis disease transcriptome},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  volume = {158},
  number = {2},
  pages = {542--554},
  doi = {10.1016/j.jaci.2026.01.033}
}
Kostenlos starten →